Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 59

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 8
Chunk 59
---
,917 
  
    CAR-T
    Therapeutics 
     7,691  
     8,535 
  
    Other 
     118  
     139 
  
    Total 
    $17,651  
    $21,591 
  
    Total assets 
    $17,651  
    $21,591 

Operating
costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing
the enterprise.

16

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Information
included in this Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning
future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,”
“anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which
are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different
from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties
and factors include, but are not limited to, those factors set forth in our Annual Report on Form 10-K for the fiscal year ended October
31, 2024. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned
not to unduly rely on such forward-looking statements when evaluating the information presented in this Report.

GENERAL

We
discuss the description of our business in the Notes to our Condensed Consolidated Financial Statements.

RESULTS
OF OPERATIONS

Three
months ended July 31, 2025 compared with three months ended July 31, 2024

Revenue

We
had no revenue during the three-month periods ended July 31, 2025 and 2024.

We
have not generated any revenue to date from